Project objective

Non-small cell lung cancer ( NSCLC) accounts for around 85% of all lung cancers.
Among these, a minority of patients present a rare genetic alteration: a translocation of the ALK(anaplastic lymphoma kinase) gene, found in around 3-5% of cases, often in younger patients who are non-smokers or light smokers.

This mutation makes tumor cells sensitive to a targeted class of treatments: ALK tyrosine kinase inhibitors (ALK TKIs), which have significantly improved first- and second-line treatment.

Tracking the treatment regimens and clinical evolution of these patients is essential to better understand their care pathways, optimize management and document the real-life efficacy of treatments.

‍

First data extraction (2025)

Main objective
To describe the demographic and clinical characteristics of advanced non-small-cell lung cancer (aNSCLC) patients with ALK+ alteration included in the LUCC cohort and treated as first-line patients with targeted therapies (ALK TKIs).

Secondary objectives

Analyze first- and second-line treatment paths.
Characterize patients who received second-line treatment.

‍

Second data extraction (2026)

Primary objective
To evaluate the efficacy of first-line treatments in a real-life setting.

Secondary objectives

Describe the profiles of patients treated in the first or second line.
Analyze treatment sequences, including the use of surgery or radiotherapy.
Study disease progression and outcomes associated with second-line treatments.

Target population

Inclusion criteria:
- Patients aged 18 and over,
- Diagnosed with advanced non-small-cell lung cancer with ALK alteration confirmed by histological analysis.
- Treated in the first line with an ALK TKI-type targeted therapy between January 31, 2020 and January 31, 2024 for the first extraction, or until January 31, 2025 for the second extraction.

Exclusion criteria
- Patients taking part in an interventional clinical trial for the first-line treatment of ALK+ non-small-cell lung cancer.
- Patients treated with ALK TKIs whose ALK+ mutation has not been confirmed.

‍

Data source

The Monarch project is based on data from the LuCC - Lung Cancer Cohort. A database designed specifically to monitor lung cancer patients.

‍

Patients

Why take part in the project?

Some of your medical and administrative data is collected when you are treated in a healthcare facility. This data is useful for the advancement of research.

This research, conducted in the public interest, aims to develop knowledge in order to develop new treatments or improve the overall management of patients suffering from the same disease as you. If you agree to your data being used for this study, you will not have to make any additional visits or undergo any additional examinations.

Only information already in your medical file will be collected. No directly identifying data (surname, first name or contact details) will be included in the cohorts.

If you wish to object to the processing of your data, you may exercise your rights by informing :

your hospital doctor treating you for lung cancer follow-up or ;
‍
Lifen's Data Protection Officer at the following address: dpo@lifen.fr ;
‍
or by completing the opposition form.

‍